Latest Period
Q1 2026
Security Snapshot
Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) Institutional Ownership
CUSIP: 87650L103
13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026
Institutions Reporting
253
Shares (Excl. Options)
45,142,311
Price
$70.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- TARS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 45,142,311
- Total 13F value
- $3,166,900,867
- Portfolio coverage rank
- 0%
- Share change
- +1,091,371
- Value change
- +$67,222,417
- Number of holders
- 253
- Shares outstanding
- 42,282,321
- SEC-reported price per share
- $62.97
- Insider filing price
- $62.97
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TARS - Tarsus Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 87650L103.
- 253 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 253 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $3,166,900,867 to $7,112.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 253 institutions filings for Q1 2026.
Security key
87650L103
Latest holder period
Q1 2026
13F holders
253
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
TARS full holder history
Tarsus Pharmaceuticals, Inc. SEC filings
Tarsus Pharmaceuticals, Inc. company facts
Tarsus Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87650L103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
TARS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 8.5% | +19% | $261,540,000 | +$43,590,000 | 3,600,000 | +20% | Deep Track Capital, LP | 31 Mar 2026 |
| RTW INVESTMENTS, LP | 8.1% | $134,159,372 | 3,424,180 | RTW Investments, LP | 30 Jun 2025 | |||
| BlackRock, Inc. | 7.4% | $153,770,784 | 3,092,735 | BlackRock, Inc. | 31 Mar 2025 | |||
| JANUS HENDERSON GROUP PLC | 5.3% | $162,805,962 | 2,240,963 | JANUS HENDERSON GROUP PLC | 31 Mar 2026 | |||
| MORGAN STANLEY | 4.7% | $96,628,483 | 1,943,453 | Morgan Stanley | 31 Mar 2025 | |||
| Cowen Financial Products LLC | 4.9% | $94,926,816 | 1,909,228 | Cowen Financial Products LLC | 31 Dec 2024 | |||
| PRUDENTIAL FINANCIAL INC | 4.3% | $133,408,721 | 1,836,321 | PRUDENTIAL FINANCIAL INC | 31 Mar 2026 | |||
| JENNISON ASSOCIATES LLC | 4% | $124,385,809 | 1,712,124 | Jennison Associates LLC | 31 Mar 2026 | |||
| TANG CAPITAL MANAGEMENT LLC | 2.8% | -52% | $89,776,771 | -$95,634,047 | 1,188,624 | -52% | TANG CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
As of 31 Mar 2026, 253 institutional investors reported holding 45,142,311 shares of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS). This represents 107% of the company’s total 42,282,321 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 8.5% | 3,600,000 | +20% | 5.2% | $252,540,000 |
| BlackRock, Inc. | 8.4% | 3,552,612 | -6.3% | 0% | $249,215,733 |
| RTW INVESTMENTS, LP | 7.9% | 3,346,025 | +0.32% | 2.3% | $234,723,654 |
| Paradigm Biocapital Advisors LP | 6.1% | 2,562,154 | 0% | 3.7% | $179,735,103 |
| JANUS HENDERSON GROUP PLC | 5.3% | 2,240,963 | +16% | 0.08% | $157,222,823 |
| MORGAN STANLEY | 4.6% | 1,944,271 | -4.7% | 0.01% | $136,390,628 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 1,760,541 | 0% | 0% | $123,501,951 |
| JENNISON ASSOCIATES LLC | 4% | 1,712,124 | -23% | 0.08% | $120,105,500 |
| Assenagon Asset Management S.A. | 3% | 1,280,194 | +14% | 0.14% | $89,805,609 |
| BANK OF AMERICA CORP /DE/ | 2.8% | 1,194,377 | +58% | 0.01% | $83,785,547 |
| TANG CAPITAL MANAGEMENT LLC | 2.8% | 1,188,624 | 0% | 4.2% | $83,381,974 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 1,121,091 | +18% | 0% | $78,658,404 |
| STATE STREET CORP | 2.3% | 978,212 | +5.3% | 0% | $68,621,572 |
| Driehaus Capital Management LLC | 2.2% | 926,125 | -21% | 0.48% | $64,967,669 |
| LORD, ABBETT & CO. LLC | 2% | 842,313 | -1.6% | 0.19% | $59,088,000 |
| D. E. Shaw & Co., Inc. | 1.9% | 791,146 | +29% | 0.04% | $55,498,892 |
| Invesco Ltd. | 1.8% | 742,497 | -27% | 0.01% | $52,086,165 |
| FMR LLC | 1.7% | 733,334 | +13% | 0% | $51,443,395 |
| Frazier Life Sciences Management, L.P. | 1.7% | 728,644 | 0% | 1.3% | $51,114,377 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 564,579 | +383% | 0.03% | $39,605,217 |
| Clearbridge Investments, LLC | 1.3% | 545,351 | +7.8% | 0.03% | $38,256,396 |
| TORONTO DOMINION BANK | 1.2% | 510,253 | 0% | 0.07% | $35,794,248 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.2% | 499,853 | -15% | 0.06% | $35,065,000 |
| GOLDMAN SACHS GROUP INC | 1% | 439,626 | +16% | 0% | $30,839,764 |
| LOOMIS SAYLES & CO L P | 0.96% | 407,836 | -7.7% | 0.04% | $28,609,695 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 113 | $7,112 | $62.97 | 2 | |
| 2026 Q1 | 45,142,311 | $3,166,900,867 | +$67,222,417 | $70.15 | 253 |
| 2025 Q4 | 44,051,147 | $3,606,397,271 | -$100,796,094 | $81.88 | 246 |
| 2025 Q3 | 44,893,892 | $2,667,774,204 | -$49,024,662 | $59.43 | 219 |
| 2025 Q2 | 46,131,357 | $1,868,819,935 | +$92,954,236 | $40.51 | 204 |
| 2025 Q1 | 43,564,795 | $2,238,109,644 | +$155,550,097 | $51.37 | 191 |
| 2024 Q4 | 40,257,261 | $2,228,992,305 | -$65,425,283 | $55.37 | 192 |
| 2024 Q3 | 43,391,345 | $1,426,965,052 | +$102,534,235 | $32.89 | 161 |
| 2024 Q2 | 40,066,753 | $1,089,006,566 | +$6,596,629 | $27.18 | 147 |
| 2024 Q1 | 39,323,641 | $1,429,414,516 | +$260,798,405 | $36.35 | 155 |
| 2023 Q4 | 32,126,860 | $650,570,328 | +$49,625,202 | $20.25 | 114 |
| 2023 Q3 | 29,793,106 | $529,411,112 | +$139,188,159 | $17.77 | 105 |
| 2023 Q2 | 21,435,682 | $387,312,097 | +$39,178,138 | $18.07 | 92 |
| 2023 Q1 | 20,057,814 | $252,130,256 | -$6,023,437 | $12.57 | 73 |
| 2022 Q4 | 20,531,051 | $300,987,054 | +$5,059,618 | $14.66 | 67 |
| 2022 Q3 | 20,489,091 | $350,771,070 | +$9,266,431 | $17.12 | 72 |
| 2022 Q2 | 19,980,650 | $291,715,823 | +$98,791,820 | $14.60 | 70 |
| 2022 Q1 | 13,210,299 | $222,212,113 | -$29,618,514 | $16.82 | 50 |
| 2021 Q4 | 13,072,993 | $294,217,317 | +$4,316,413 | $22.50 | 43 |
| 2021 Q3 | 12,869,541 | $277,366,339 | -$12,449,066 | $21.55 | 43 |
| 2021 Q2 | 13,061,656 | $378,528,053 | +$8,240,890 | $28.98 | 44 |
| 2021 Q1 | 12,761,893 | $410,350,129 | -$213,790 | $32.23 | 41 |
| 2020 Q4 | 12,759,585 | $523,637,183 | +$523,637,191 | $41.33 | 39 |